-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Contineum Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q4 2024.
- Contineum Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $0.000.
- Contineum Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2024 was $0.000, a 100% decline year-over-year.
- Contineum Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $0.000, a 100% decline from 2023.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)